[英夫利西单抗辅助治疗类风湿性关节炎的效果观察] 英夫利西单抗多少钱
[摘要] 目的 探讨英夫利西单抗在类风湿性关节炎治疗中的临床应用价值。 方法 将2010年3月～2011年9月在本院诊治的70例类风湿性关节炎患者随机分成两组：实验组35例，对照组35例。对照组单纯给予甲氨蝶呤口服治疗；实验组则再给予英夫利西单抗静脉滴注治疗。观察比较两组患者的临床疗效、实验室指标和临床观察指标水平、不良反应发生情况。 结果 实验组患者的总有效率显著高于对照组（P ＜ 0.05）；实验组患者的类风湿因子（RF）、C反应蛋白（CRP）、血沉（ESR）指标水平均显著低于对照组（P ＜ 0.05）；实验组患者的晨僵时间、关节肿胀数、关节压痛数明显少于对照组（P ＜ 0.05）；实验组的总不良反应发生率显著低于对照组（P ＜ 0.05）。 结论 临床上应用英夫利西单抗辅助治疗类风湿性关节炎的效果显著。
[关键词] 类风湿性关节炎；英夫利西单抗；临床疗效
[中图分类号] R684.3 [文献标识码] A [文章编号] 1673-7210（2012）08（b）-0068-02
Clinical efficacy of Infliximab for the auxiliary treatment of rheumatoid arthritis
CAI Ming
Department of Orthopaedics, Chongqing Hospital of Traditional Chinese Medicine, Chongqing 400011, China
[Abstract] Objective To investigate the clinical value about Infliximab for the treatment of rheumatoid arthritis. Methods 70 cases of rheumatoid arthritis patients admitted to hospital from March 2010 to September 2011 were randomly divided into two groups, control group (n = 35) and treatment group (n = 35). The control group was treated with Methotrexate only, but the treatment group was also treated with Infliximab. The clinical effects, the laboratory parameters and clinical observations target levels, and the incidence of adverse reactions were observed and compared. Results The total effective rate in the treatment group was significantly higher than the control group (P ＜ 0.05); the index value of RF, CRP, ESR in the treatment group was significantly lower than the control group (P ＜ 0.05); the duration of morning stiffness, number of swollen joints and joint tenderness in the treatment group were significantly less than the control group (P ＜ 0.05); the total incidence of adverse reactions in the treatment group was significantly lower than the control group (P ＜ 0.05). Conclusion There is a significant clinical efficacy of Infliximab for the treatment of rheumatoid arthritis.
[Key words] Rheumatoid arthritis; Infliximab; Clinical efficacy
类风湿性关节炎（rheumatoid arthritis，RA）是一种常见的以关节滑膜炎为特征性症状的慢性炎症性自身免疫性疾病[1]。RA的主要临床表现为关节疼痛、肿胀，关节内软骨和骨结构的破坏，关节功能障碍等，RA持续反复发作易引起肢体严重畸形甚至残废，严重影响了患者的生活质量[2]。目前，临床上主要采用非甾体类抗炎药、青霉胺、肾上腺皮质激素、免疫抑制剂等药物治疗。本研究采用英夫利西单抗辅助治疗类风湿性关节炎取得了良好的临床效果，现报道如下：
1 资料与方法
1.1 一般资料
选择2010年3月～2011年9月我院确诊的类风湿性关节炎患者70例，所有患者符合1987年美国风湿病学会修订的RA相关诊断标准，排除伴心血管疾病、肝肾功能不全、严重感染、精神病等病史患者[3]，患者均已签署医院伦理委员拟定的知情同意书。将70例患者随机分成两组：①实验组35例，男15例，女20例；平均年龄（55.0±12.8）岁；平均病程（3.62±2.50）年；关节功能分级：Ⅰ级8例，Ⅱ级17例，Ⅲ级10例。②对照组35例，男16例，女19例；平均年龄（54.8±12.7）岁；平均病程（3.65±2.50）年；关节功能分级：Ⅰ级9例，Ⅱ级16例，Ⅲ级10例。两组的性别、年龄、病程、关节功能分级等一般资料差异均无统计学意义（P ＞ 0.05），具有可比性。